Literature DB >> 16565437

The saponin-mediated enhanced uptake of targeted saporin-based drugs is strongly dependent on the saponin structure.

Christopher Bachran1, Mark Sutherland, Iring Heisler, Philipp Hebestreit, Matthias F Melzig, Hendrik Fuchs.   

Abstract

Saponins are a group of plant glycosides consisting of a steroid or triterpenoid aglycone to which one or more sugar chains are attached. They exhibit cell membrane-permeabilizing properties and, thus, have been investigated for their therapeutic potential. Recently, at a non-permeabilizing concentration saponinum album from Gypsophila paniculata L. has been described to enhance the cytotoxicity of a chimeric toxin in a cell culture model. To elucidate whether this enhancing effect is also mediated by other saponins, we analyzed the ability of seven different saponins to enhance the cytotoxicity of a targeted chimeric toxin. The chimeric toxin is composed of saporin, a plant ribosome-inactivating toxin, a cleavable adapter, and human epidermal growth factor (EGF). Cytotoxicity on EGF receptor (EGFR)-bearing cells was analyzed both alone and after combined application of saponin and chimeric toxin. Only two of the tested saponins, quillajasaponin and saponinum album, enhanced cytotoxicity by more than 1,000-fold, whereas the enhancement factors of the other saponins were only approximately 10-fold. In contrast to saponinum album, quillajasaponin enhanced the cytotoxicity both on control cells lacking EGFR and on target cells, indicating that, in this case, the enhancement is not target cell receptor specific. This is also the case for some of the saponins with low enhancement factors. Saponinum album resulted in a more than 13,600-fold receptor-specific enhancement, decreasing the 50% inhibitory concentration (IC(50)) from 2.4 nM to 0.18 pM, which renders it the best option to promote saporin-3-based drug uptake while retaining specificity for the EGFR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16565437     DOI: 10.1177/153537020623100407

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  7 in total

Review 1.  Targeting antibodies to the cytoplasm.

Authors:  Andrea L J Marschall; André Frenzel; Thomas Schirrmann; Manuela Schüngel; Stefan Dübel
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

2.  Depletion of inflammatory dendritic cells with anti-CD209 conjugated to saporin toxin.

Authors:  Michael N Alonso; Josh G Gregorio; Matthew G Davidson; Joseph C Gonzalez; Edgar G Engleman
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

3.  Reductive methylation and mutation of an anthrax toxin fusion protein modulates its stability and cytotoxicity.

Authors:  Christopher Bachran; Pradeep K Gupta; Silke Bachran; Clinton E Leysath; Benjamin Hoover; Rasem J Fattah; Stephen H Leppla
Journal:  Sci Rep       Date:  2014-04-23       Impact factor: 4.996

4.  The distribution of saponins in vivo affects their synergy with chimeric toxins against tumours expressing human epidermal growth factor receptors in mice.

Authors:  C Bachran; A Weng; D Bachran; S B Riese; N Schellmann; M F Melzig; H Fuchs
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

5.  Effects of saponins against clinical E. coli strains and eukaryotic cell line.

Authors:  Michał Arabski; Aneta Węgierek-Ciuk; Grzegorz Czerwonka; Anna Lankoff; Wiesław Kaca
Journal:  J Biomed Biotechnol       Date:  2012-02-21

Review 6.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 7.  Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies.

Authors:  Hendrik Fuchs; Nicole Niesler; Alexandra Trautner; Simko Sama; Gerold Jerz; Hossein Panjideh; Alexander Weng
Journal:  Biomedicines       Date:  2017-03-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.